Global Clinical Trials Market Is Expected to Reach USD 85.01 Billion By 2030

The global clinical trials market size was valued at USD 53.92 Billion in 2022 and is expected to reach USD 85.01 Billion by 2030, growing at a compound annual growth rate (CAGR) of 5.93% during the forecast period.

Clinical trials are research studies that evaluate the safety, efficacy, and side effects of new drugs, medical devices, and treatments. These trials are essential to advance medical knowledge, develop new therapies, and improve patient care. Clinical trials involve three main phases, with each phase designed to answer specific questions about the drug or treatment being tested. Phase I trials evaluate safety and dosage, phase II assesses the efficacy and side effects, and phase III compares the treatment to existing therapies. Clinical trials require the participation of volunteers, who are carefully screened and monitored throughout the trial.

Participants are required to provide informed consent and can withdraw from the trial at any time. Clinical trials are conducted under strict regulatory oversight and ethical guidelines to ensure patient safety and data integrity.

The global clinical trials market is predicted to surge exponentially due to the increasing prevalence of chronic and infectious diseases, demand for personalized medicine, advancements in technology, and rising investment by pharmaceutical & biotechnology companies. However, the market also faces several restraints, including the high cost of conducting trials, complex regulatory requirements, and the shortage of skilled professionals.

The COVID-19 pandemic has also disrupted clinical trials, leading to delays and cancellations. Nonetheless, the clinical trials industry presents several opportunities for growth, including the increasing focus on precision medicine, the emergence of real-world evidence & patient-generated health data, and collaborations between pharmaceutical companies, CROs, & academic institutions. These factors are predicted to create remunerative opportunities for the growth of the industry.

The global clinical trials market is segmented based on phase, study design, indication, and region.

Based on phase, the market bifurcated into Phase I, Phase II, Phase III, and Phase IV. The Phase III segment held the largest market share in 2022 and is further predicted to grow rapidly at a notable CAGR during the forecast period. The main reason for the growth of this segment is its critical role in drug development. Phase III trials are designed to compare the safety and efficacy of new treatments to existing therapies, providing important data for regulatory approval and market access. The increasing prevalence of chronic and infectious diseases and demand for personalized medicine is driving the need for new and innovative treatments, leading to a surge in Phase III trials. Moreover, the emergence of real-world evidence and patient-generated health data is expected to transform the Phase III landscape, enabling more efficient and effective trials.

Based on study design, the clinical trials industry is bifurcated into observational, interventional, and expanded access. The interventional design segment held the dominating market share in 2022 and is further projected to grow rapidly at a significant CAGR during the forecast period.

The interventional design segment of the clinical trials market is expected to experience significant growth due to the increasing demand for innovative and effective treatments. Interventional trials involve the use of a new treatment or drug and are designed to evaluate its safety, efficacy, and side effects. These trials play a crucial role in the development of new therapies and are essential for gaining regulatory approval and market access. The rising prevalence of chronic & infectious diseases and demand for personalized medicine is driving the need for new and innovative treatments, leading to a surge in interventional trials. Moreover, advancements in technology and data analytics are expected to transform interventional trial design, making them more efficient and effective.

Based on indication, the market is segmented into gastrointestinal, cardiovascular, autoimmune/inflammation, pain management, CNS condition, cancer, mental disorders, oncology, diabetes, obesity, and others. The oncology segment held the dominating market share in 2022 and is projected to cite a remarkable CAGR during the forecast period.

Based on region, the North American region held the dominating clinical trials market share in 2022 and is further predicted to grow at an exponential CAGR during the forecast period. North America is a major player in the clinical trials market, with the United States accounting for the majority of the region's market share.

The growth of the market in North America is driven by several factors, including the increasing prevalence of chronic & infectious diseases, the demand for personalized medicine, and the presence of a well-established pharmaceutical industry. Furthermore, the region has a favorable regulatory environment, with the FDA playing a crucial role in the approval and oversight of clinical trials. The COVID-19 pandemic has also spurred growth in the North American clinical trials market, with a surge in trials for vaccines and treatments. Therefore, the North American clinical trials market is expected to continue growing due to the region's strong healthcare infrastructure, favorable regulatory environment, and increasing demand for innovative treatments.

This review is based on a report by Zion Market Research, titled “Clinical Trials Market By Phase (Phase I, Phase II, Phase III, Phase IV) By Study Design (Observational, Interventional, Expanded Access) By Indication (Gastrointestinal, Cardiovascular, Autoimmune/Inflammation, Pain Management, CNS Condition, Cancer, Mental Disorders, Oncology, Diabetes, Obesity, Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2023 – 2030.”- Report at https://www.zionmarketresearch.com/report/clinical-trials-market

Recent Developments

• In October 2021, Novartis announced the completion of its Phase III clinical trial for a new sickle cell disease treatment. The trial showed a significant reduction in the rate of sickle cell-related pain crises compared to the placebo, and the company plans to submit the drug for regulatory approval in 2022.
• In June 2021, AstraZeneca announced positive results from its Phase III clinical trial for a new lung cancer treatment. The trial showed a significant improvement in progression-free survival compared to the placebo, and the company plans to submit the drug for regulatory approval.
• In September 2021, Pfizer and BioNTech announced the completion of a Phase II/III trial for their COVID-19 vaccine in children aged 5 to 11. The trial showed a favorable safety profile and robust antibody responses, and the companies plan to seek regulatory authorization for the vaccine in this age group.

The global clinical trials market is dominated by players such as:

• IQVIA
• PPD
• Covance
• Parexel International
• Syneos Health
• Charles River Laboratories
• ICON plc
• Medpace
• PRA Health Sciences
• WuXi AppTec
• Chiltern International
• Celerion
• Envigo
• Eurofins Scientific
• Frontage Laboratories
• Laboratory Corporation of America Holdings (LabCorp)
• Novotech Pty Ltd.
• Pharmaron
• Pharmaceutical Product Development LLC (PPD)
• QuintilesIMS (now IQVIA)
• Among Others.

The report segment of the global clinical trials market is as follows:

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design

• Observational
• Interventional
• Expanded Access

By Indication

• Gastrointestinal
• Cardiovascular
• Autoimmune/Inflammation
• Pain management
• CNS condition
• Cancer
• Mental disorders
• Oncology
• Diabetes
• Obesity
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com